Antibiotic Timing Not a Significant Factor in Outcomes of Febrile Neutropenia
the Cancer Therapy Advisor take:
No significant correlation was established between the time from antibiotic administration and febrile neutropenia (FN) outcomes or complication rates in overall FN cases, according to an article published online in the journal Supportive Care in Cancer.
The authors evaluated 1,001 consecutive FN cases (diagnosed between November 1, 2011 and August 31, 2014) from the Neutropenic Fever Registry.
Antibiotic timing cutoffs were established as less than or equal to 1 hour versus greater than 1 hour, less than or equal to 2 hours versus greater than 2 hours, less than or equal to 3 hours versus greater than 3 hours, and less than or equal to 4 hours versus greater than 4 hours.
Analysis determined the median length of time from triage to antibiotics administration was 140 minutes (interquartile range, 110 to 180 minutes).
Results showed the time from triage to antibiotics was not related to FN outcomes, after adjusting for potential confounders, for each time cutoff.
Furthermore, the time to antibiotic administration was not found to be significantly associated with mortality in FN episodes with bacteremia, severe sepsis, or septic shock.
The investigators noted procalcitonin concentration and the Multinational Association for Supportive Care in Cancer (MASCC) risk index score appeared to be more critical determinants of FN patient outcomes.
No significant correlation was established between the time from antibiotic administration and febrile neutropenia outcomes.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- High Red Meat Intake and Cancer
- Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
- The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL